Regulation of human IgE synthesis.

Donata Vercelli, H. H. Jabara, R. S. Geha

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Allergic diseases result from the interaction with IgE bound to cell surface receptors. Therefore, rational therapeutic approaches to allergic diseases would be aimed at decreasing IgE and/or at blocking the binding of IgE to effector cells such as mast cells and monocytes. Our investigation of the mechanism of IgE synthesis in man shows that IgE synthesis by peripheral blood mononuclear cells (PBMC) absolutely requires the presence of IL-4 and requires endogenous IL-6, because antibody to IL-6 inhibits IgE production completely. IgE synthesis requires T/B cell contact and involves interactions between B cell surface MHC Class II molecules and T cell surface receptors, as antibodies to both of these cell surface molecules inhibit IgE synthesis. Furthermore, alloreactive T cell clones which are unable to engage the B cell MHC Class II molecules fail to induce IgE synthesis in spite of their ability to secrete IL-4. Studies on the immunoglobulin sites that are involved in IgE binding to high affinity receptors on mast cells and basophils have used recombinant fragments of IgE to block mast cell binding. These studies suggest that a stretch of 76 amino acids which straddles the C epsilon 2 and C epsilon 3 domains is essential for this binding. Parallel studies on IgE binding to low affinity receptors on monocytes and B cells suggest that sequences within C epsilon 3 are involved in this binding. Peptides or analogues that inhibit IgE binding to its cellular receptors may be useful in the treatment of allergic diseases.

Original languageEnglish (US)
Pages (from-to)111-115
Number of pages5
JournalInternational Reviews of Immunology
Volume5
Issue number2
StatePublished - 1989
Externally publishedYes

Fingerprint

Immunoglobulin E
B-Lymphocytes
Mast Cells
Cell Surface Receptors
Interleukin-4
Monocytes
Interleukin-6
Basophils
Antibodies
T-Cell Antigen Receptor
Immunoglobulins
Blood Cells
Clone Cells
T-Lymphocytes
Amino Acids
Peptides

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Vercelli, D., Jabara, H. H., & Geha, R. S. (1989). Regulation of human IgE synthesis. International Reviews of Immunology, 5(2), 111-115.

Regulation of human IgE synthesis. / Vercelli, Donata; Jabara, H. H.; Geha, R. S.

In: International Reviews of Immunology, Vol. 5, No. 2, 1989, p. 111-115.

Research output: Contribution to journalArticle

Vercelli, D, Jabara, HH & Geha, RS 1989, 'Regulation of human IgE synthesis.', International Reviews of Immunology, vol. 5, no. 2, pp. 111-115.
Vercelli, Donata ; Jabara, H. H. ; Geha, R. S. / Regulation of human IgE synthesis. In: International Reviews of Immunology. 1989 ; Vol. 5, No. 2. pp. 111-115.
@article{8b30443c85e74ed8bec9c40bf817845a,
title = "Regulation of human IgE synthesis.",
abstract = "Allergic diseases result from the interaction with IgE bound to cell surface receptors. Therefore, rational therapeutic approaches to allergic diseases would be aimed at decreasing IgE and/or at blocking the binding of IgE to effector cells such as mast cells and monocytes. Our investigation of the mechanism of IgE synthesis in man shows that IgE synthesis by peripheral blood mononuclear cells (PBMC) absolutely requires the presence of IL-4 and requires endogenous IL-6, because antibody to IL-6 inhibits IgE production completely. IgE synthesis requires T/B cell contact and involves interactions between B cell surface MHC Class II molecules and T cell surface receptors, as antibodies to both of these cell surface molecules inhibit IgE synthesis. Furthermore, alloreactive T cell clones which are unable to engage the B cell MHC Class II molecules fail to induce IgE synthesis in spite of their ability to secrete IL-4. Studies on the immunoglobulin sites that are involved in IgE binding to high affinity receptors on mast cells and basophils have used recombinant fragments of IgE to block mast cell binding. These studies suggest that a stretch of 76 amino acids which straddles the C epsilon 2 and C epsilon 3 domains is essential for this binding. Parallel studies on IgE binding to low affinity receptors on monocytes and B cells suggest that sequences within C epsilon 3 are involved in this binding. Peptides or analogues that inhibit IgE binding to its cellular receptors may be useful in the treatment of allergic diseases.",
author = "Donata Vercelli and Jabara, {H. H.} and Geha, {R. S.}",
year = "1989",
language = "English (US)",
volume = "5",
pages = "111--115",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Regulation of human IgE synthesis.

AU - Vercelli, Donata

AU - Jabara, H. H.

AU - Geha, R. S.

PY - 1989

Y1 - 1989

N2 - Allergic diseases result from the interaction with IgE bound to cell surface receptors. Therefore, rational therapeutic approaches to allergic diseases would be aimed at decreasing IgE and/or at blocking the binding of IgE to effector cells such as mast cells and monocytes. Our investigation of the mechanism of IgE synthesis in man shows that IgE synthesis by peripheral blood mononuclear cells (PBMC) absolutely requires the presence of IL-4 and requires endogenous IL-6, because antibody to IL-6 inhibits IgE production completely. IgE synthesis requires T/B cell contact and involves interactions between B cell surface MHC Class II molecules and T cell surface receptors, as antibodies to both of these cell surface molecules inhibit IgE synthesis. Furthermore, alloreactive T cell clones which are unable to engage the B cell MHC Class II molecules fail to induce IgE synthesis in spite of their ability to secrete IL-4. Studies on the immunoglobulin sites that are involved in IgE binding to high affinity receptors on mast cells and basophils have used recombinant fragments of IgE to block mast cell binding. These studies suggest that a stretch of 76 amino acids which straddles the C epsilon 2 and C epsilon 3 domains is essential for this binding. Parallel studies on IgE binding to low affinity receptors on monocytes and B cells suggest that sequences within C epsilon 3 are involved in this binding. Peptides or analogues that inhibit IgE binding to its cellular receptors may be useful in the treatment of allergic diseases.

AB - Allergic diseases result from the interaction with IgE bound to cell surface receptors. Therefore, rational therapeutic approaches to allergic diseases would be aimed at decreasing IgE and/or at blocking the binding of IgE to effector cells such as mast cells and monocytes. Our investigation of the mechanism of IgE synthesis in man shows that IgE synthesis by peripheral blood mononuclear cells (PBMC) absolutely requires the presence of IL-4 and requires endogenous IL-6, because antibody to IL-6 inhibits IgE production completely. IgE synthesis requires T/B cell contact and involves interactions between B cell surface MHC Class II molecules and T cell surface receptors, as antibodies to both of these cell surface molecules inhibit IgE synthesis. Furthermore, alloreactive T cell clones which are unable to engage the B cell MHC Class II molecules fail to induce IgE synthesis in spite of their ability to secrete IL-4. Studies on the immunoglobulin sites that are involved in IgE binding to high affinity receptors on mast cells and basophils have used recombinant fragments of IgE to block mast cell binding. These studies suggest that a stretch of 76 amino acids which straddles the C epsilon 2 and C epsilon 3 domains is essential for this binding. Parallel studies on IgE binding to low affinity receptors on monocytes and B cells suggest that sequences within C epsilon 3 are involved in this binding. Peptides or analogues that inhibit IgE binding to its cellular receptors may be useful in the treatment of allergic diseases.

UR - http://www.scopus.com/inward/record.url?scp=0024959075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024959075&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 111

EP - 115

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 2

ER -